Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cisplatin
/ administration & dosage
Disease Progression
Docetaxel
/ administration & dosage
Drug Administration Schedule
Female
Head and Neck Neoplasms
/ drug therapy
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Progression-Free Survival
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Time Factors
Carcinoma, squamous cell
Cisplatin
Docetaxel
Head and neck neoplasms
Journal
The Korean journal of internal medicine
ISSN: 2005-6648
Titre abrégé: Korean J Intern Med
Pays: Korea (South)
ID NLM: 8712418
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
01
07
2017
accepted:
07
02
2018
pubmed:
20
6
2018
medline:
4
3
2020
entrez:
20
6
2018
Statut:
ppublish
Résumé
We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, 18 patients with previously diagnosed R/M HNSCC were treated with combination chemotherapy of weekly docetaxel 35 mg/m2 (day 1 and 8) and cisplatin 70 mg/m2 (day 1) as first-line chemotherapy, repeated every 3 weeks. Partial response and stable disease were observed in six patients (33.3%; 95% confidence interval [CI], 11.1% to 55.6%) and six patients (33.3%; 95% CI, 11.1% to 55.6%), respectively. The median overall survival and progression-free survival were 11.26 months (95% CI, 8.87 to 15.83) and 5.68 months (95% CI, 4.80 to 6.51), respectively. The major toxicity was grade 1/2 anemia (50%). Grade 3/4 neutropenia was observed in one patient (5.6%). Among the non-hematologic toxicities, grade 1/2 hepatotoxicity was most common (22.2%), and grade 3/4 infection was observed in one patient (5.6%). There was no treatment-related mortality. For patients with R/M HNSCC, a cisplatin and weekly docetaxel regimen showed high efficacy with tolerable toxicity as a first-line treatment.
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
METHODS
METHODS
In this study, 18 patients with previously diagnosed R/M HNSCC were treated with combination chemotherapy of weekly docetaxel 35 mg/m2 (day 1 and 8) and cisplatin 70 mg/m2 (day 1) as first-line chemotherapy, repeated every 3 weeks.
RESULTS
RESULTS
Partial response and stable disease were observed in six patients (33.3%; 95% confidence interval [CI], 11.1% to 55.6%) and six patients (33.3%; 95% CI, 11.1% to 55.6%), respectively. The median overall survival and progression-free survival were 11.26 months (95% CI, 8.87 to 15.83) and 5.68 months (95% CI, 4.80 to 6.51), respectively. The major toxicity was grade 1/2 anemia (50%). Grade 3/4 neutropenia was observed in one patient (5.6%). Among the non-hematologic toxicities, grade 1/2 hepatotoxicity was most common (22.2%), and grade 3/4 infection was observed in one patient (5.6%). There was no treatment-related mortality.
CONCLUSION
CONCLUSIONS
For patients with R/M HNSCC, a cisplatin and weekly docetaxel regimen showed high efficacy with tolerable toxicity as a first-line treatment.
Identifiants
pubmed: 29914230
pii: kjim.2017.234
doi: 10.3904/kjim.2017.234
pmc: PMC6718762
doi:
Substances chimiques
Docetaxel
15H5577CQD
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1107-1115Références
Ann Oncol. 1999 Jan;10(1):119-22
pubmed: 10076732
Ann Oncol. 1999 Jun;10(6):701-6
pubmed: 10442193
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Ann Oncol. 2000 Jul;11(7):845-9
pubmed: 10997812
Oncology (Williston Park). 2000 Nov;14(11A):163-94
pubmed: 11195409
Ann Oncol. 2001 Feb;12(2):199-202
pubmed: 11300324
J Clin Oncol. 2002 Mar 15;20(6):1593-9
pubmed: 11896109
J Clin Oncol. 2002 Sep 1;20(17):3683-90
pubmed: 12202670
Cent Eur J Public Health. 2003 Sep;11(3):177-9
pubmed: 14514174
Ann Oncol. 2004 Sep;15(9):1358-65
pubmed: 15319242
Oncologist. 2004;9(5):538-45
pubmed: 15477638
Gan To Kagaku Ryoho. 2005 Nov;32(12):1915-8
pubmed: 16282726
Cancer. 2006 Jan 1;106(1):106-11
pubmed: 16329139
J Clin Oncol. 1992 Aug;10(8):1245-51
pubmed: 1634913
Chest. 2006 Apr;129(4):1031-8
pubmed: 16608954
Cancer J. 2006 Jan-Feb;12(1):69-72
pubmed: 16613665
Clin Pharmacokinet. 2006;45(6):611-22
pubmed: 16719542
Clin Cancer Res. 2006 Oct 1;12(19):5786-93
pubmed: 17020985
J Clin Oncol. 1992 Feb;10(2):257-63
pubmed: 1732427
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
pubmed: 18287387
J BUON. 2008 Apr-Jun;13(2):199-203
pubmed: 18555465
N Engl J Med. 2008 Sep 11;359(11):1143-54
pubmed: 18784104
Cancer Chemother Pharmacol. 2009 Dec;65(1):27-32
pubmed: 19381630
J Natl Compr Canc Netw. 2009 Apr;7(4):350-91
pubmed: 19406039
Cancer. 2009 Oct 1;115(19):4504-13
pubmed: 19634157
Acta Otolaryngol. 2010 Feb;130(2):293-9
pubmed: 19680990
Lung Cancer. 2010 Jul;69(1):94-8
pubmed: 19796840
Anticancer Drugs. 2010 Jun;21(5):553-8
pubmed: 20220515
Int J Cancer. 2011 Apr 1;128(7):1532-45
pubmed: 20503270
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Eur J Cancer. 2010 Jul;46(11):2088-96
pubmed: 20537890
Ann Oncol. 2011 Feb;22(2):417-23
pubmed: 20696678
J Clin Oncol. 2010 Sep 20;28(27):4142-8
pubmed: 20697079
Am J Clin Oncol. 2011 Oct;34(5):472-7
pubmed: 20938321
Clin Invest Med. 2011 Feb 01;34(1):E8-13
pubmed: 21291636
Jpn J Clin Oncol. 2011 May;41(5):630-6
pubmed: 21297121
Radiother Oncol. 2011 Jul;100(1):49-55
pubmed: 21429609
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Int J Cancer. 2012 Sep 1;131(5):1179-86
pubmed: 22020866
ISRN Oncol. 2012;2012:159568
pubmed: 22655205
Eur J Cancer. 2012 Nov;48(17):3198-204
pubmed: 22795584
Cancer Sci. 2012 Dec;103(12):2127-34
pubmed: 22937809
Cancer Chemother Pharmacol. 2014 Jan;73(1):163-9
pubmed: 24202666
Arch Otolaryngol Head Neck Surg. 1987 Jul;113(7):762-4
pubmed: 3580159
Am J Surg. 1987 Oct;154(4):439-42
pubmed: 3661849
Cancer Res. 1998 Jan 1;58(1):5-13
pubmed: 9426048